Abstract:Based on the fact that mAb 2F5 recognizing ELDKWA-epitope on the C-domain of HIV-1 gp41 has significant neutralization potency against 90% of the investigated viruses of African, Asian, American and European strains, we attempted to characterise immunogenicity of the ELDKWA-epitope on an epitope-vaccine, and to produce ELDKWA-epitope-specific monoclonal antibodies (mAb) induced by the epitope-vaccine. The C-domain peptide (P2) and the ELDKWA-tetramer peptide [C-(ELDKWAG)4] were conjugated with BSA or P24-EC (GPKEPFRDYVDRFYK, a peptide of HIV-1 gag-protein P24, proved to be a good carrier peptide to induce an immune response to the hapten on the conjugates[18])by different methods. After the vaccination course, two P2-BSA peptide-vaccines both induced a strong antibody response against the P2-peptide by about 1:12800–25600 dilution, and a weak antibody response against the ELDKWA-epitope (1:1600–3200). The P2-P24EC and P2 (conjugated with itself) peptide-vaccines could also induce a weak antibody response against the ELDKWA-epitope (1:1600–3200), while an rgpl60 subunit vaccine induced a very weak antibody response (1:400). Interestingly, the ELDKWA-tetramer epitope-vaccine [C-(ELDKWAGVBSA] could induce a strong antibody response against the ELDKWA-epitope (1:12800–25600), i.e. It increased the level of ELDKWA-antibody eight-fold, clearly better than the P2 peptide-vaccine, and much better than the rgp160 subunit vaccine, which indicates that the immunogenicities of the ELDKWA-epitope on the ELDKWA-tetramer peptide, the C-domain peptide and rgp160 are very different. These results suggest that the ELDKWA-epitope-vaccine may be a new strategy for inducing high levels of epitope-specific neutralizing antibodies against HIV- 1. Using hybridoma-technique, a mouse monoclonal antibody recognizing the ELDKWA-epitope on ELDKWA-peptide and C-domain peptide was produced by immunization with the C-(ELDKWAG)4-BSA epitope-vaccine, which indicates a new way to produce an epitope-specific mAb, namely immunization with epitope-vaccine instead of a natural or recombinant protein immunogen.

Neutralization of HIV-1 Primary Isolate by ELDKWA-specific Murine Monoclonal Antibodies.

ELNKWA-epitope Specific Antibodies Induced by Epitope-Vaccine Recognize ELDKWA- and Other Two Neutralizing-Resistant Mutated Epitopes on HIV-1 Gp41

Characterization of Antibody Responses Against the 2F5 Epitope ELDKWA sing HIV-1 Env-Mediated Membrane Fusion and Neutralization Assays

Potent Neutralizing Monoclonal Antibodies Against Ebola Virus Infection

ELDKWA-epitope-specific monoclonal antibodies inhibit HIV env-mediated syncytium formation.

Induction of High Level of Specific Antibody Response to the Neutralizing Epitope ELDKWA on HIV-1 Gp41 by Peptide-Vaccine☆

Induction of High Levels of Antibodies Recognizing the Neutralizing Epitope Eldkwa and the D- or K-Position-Mutated Epitopes by Candidate Epitope Vaccines Against Hiv-1

Epitope-Vaccine Induces High Levels of Eldkwa-Epitope-Specific Neutralizing Antibody

A predefined epitope-specific monoclonal antibody recognizes ELDEWA-epitope just presenting on gp41 of HIV-1 O clade.

The Recombinant Immunogen with High‐Density Epitopes of ELDKWA and ELDEWA Induced Antibodies Recognizing Both Epitopes on HIV‐1 Gp41

Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41.

The Neutralizing Epitope ELDKWA on HIV-1 Gp41: Genetic Variability and Antigenicity

Mucosal Antibodies Induced by Tandem Repeat of 2f5 Epitope Block Transcytosis of Hiv-1

Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice

F(ab′)2 Fragment of a Gp41 NHR-trimer-induced IgM Monoclonal Antibody Neutralizes HIV-1 Infection and Blocks Viral Fusion by Targeting the Conserved Gp41 Pocket

Specificity and Neutralizing Capacity of Three Monoclonal Antibodies Produced against the Envelope Glycoprotein of Simian Immunodeficiency Virus Isolate 251

Development and Characterization of Neutralizing Antibodies Against Zaire Ebolavirus Glycoprotein and Protein 40

A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope.

Recombinant Multi-Epitope Vaccine Induce Predefined Epitope-Specific Antibodies Against HIV-1

Multifaceted Consequences of Anti-Gp41 Monoclonal Antibody 2F5 Binding to HIV Type 1 Virions.

Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1